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Abstract
Following an application from Laboratoire Nurilia submitted for authorisation of a health claim pursuant
to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientiﬁc
substantiation of a health claim related to ‘Condensyl® and decreases sperm DNA damage. High sperm
DNA damage is a risk factor for male subfertility/infertility’. Condensyl® is a ﬁxed combination of opuntia
fruit dry extract, N-acetyl cysteine, zinc, nicotinamide, vitamins B2, B6, B12 and E, and folic acid. The
Panel considers that Condensyl® is sufﬁciently characterised. The Panel assumes that the disease that is
the subject of the application is male infertility and that the target population for the claim includes
males wishing to increase their fertility but excludes males with clinical infertility. The Panel considers
that the reduction of DNA sperm damage is a beneﬁcial physiological effect in the context of reducing
the risk of male infertility. The applicant provided four human intervention studies conducted in males
with clinical infertility, from which no conclusions could be drawn for the scientiﬁc substantiation of the
claim. The Panel concludes that a cause and effect relationship has not been established between the
consumption of Condensyl® and reduction of DNA sperm damage in the context of reducing the risk of
male infertility.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following an application from Laboratoire Nurilia submitted for authorisation of a health claim
pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the
scientiﬁc substantiation of a health claim related to ‘Condensyl® and decreases sperm DNA damage.
High sperm DNA damage is a risk factor for male subfertility/infertility’.
The scope of the application was proposed to fall under a health claim referring to disease risk
reduction.
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA general guidance for stakeholders on health claim applications.
The food which is proposed by the applicant to be the subject of the health claim is Condensyl®, a
tablet containing a ﬁxed combination of opuntia fruit dry extract (Nopal pulpe violin powder) (100 mg),
N-acetyl cysteine (250 mg), zinc (15 mg), nicotinamide (16 mg), vitamin E (succinate) (12 mg), vitamin
B6 (pyridoxine) (1.4 mg), vitamin B2 (riboﬂavin) (1.4 mg), folic acid (0.40 mg) and vitamin B12
(cyanocobalamin) (2.5 lg). Nopal (Opuntia ﬁcus indica (L.) Mill.) powder is standardised for the content
of quercetin (5 mg/100 g), indicaxanthin (13.2 mg/100 g) and betanin (28.8 mg/100 g). The
Panel considers that the food/constituent Condensyl®, which is the subject of the health claim, is
sufﬁciently characterised.
The claimed effect proposed by the applicant is ‘reduction of sperm DNA damage (sperm nuclear
decondensation index and DNA fragmentation index), high sperm DNA damage being a risk factor for
male subfertility/infertility’. The proposed target population is ‘males in reproductive age with unknown
reason leading to subfertility’.
The Panel notes that the term ‘subfertility’ has not been deﬁned by the applicant. The Panel also
notes that infertility is clinically deﬁned by the failure to achieve a clinical pregnancy after 12 months
or more of regular unprotected sexual intercourse.
In this context, the Panel assumes that the disease that is the subject of the application is male
infertility and that the target population for the claim includes males wishing to increase their fertility
but excludes males with clinical infertility.
The Panel notes that the applicant did not provide evidence to establish that a reduction of sperm
DNA damage decreases the risk of male infertility. Therefore, the Panel considers that the reduction of
DNA sperm damage is a beneﬁcial physiological effect in the context of reducing the risk of male
infertility, as long as evidence is provided that Condensyl® induces a reduction in both DNA sperm
damage and male infertility.
The applicant provided four human intervention studies as being pertinent to the claim. The
Panel notes that all these studies were conducted in males with established clinical infertility and that
they relate to the treatment of the disease, and therefore, the effect of the intervention on the
incidence of male infertility cannot be assessed. In addition, the Panel notes that two of these studies
had no control group, and that a third study was conducted with a product not complying with the
speciﬁcations of the food for which the claim is proposed. The Panel considers that no conclusions can
be drawn from these studies for the scientiﬁc substantiation of the claim.
In the absence of evidence for an effect of Condensyl® in reducing sperm DNA damage and the
risk of male infertility in vivo in humans, the studies provided by the applicant on the proposed
mechanisms by which Condensyl® could exert the claimed effect were not considered by the Panel for
the scientiﬁc substantiation of the claim.
On the basis of data presented, the Panel concludes that a cause and effect relationship has not
been established between the consumption of Condensyl® and reduction of DNA sperm damage in the
context of reducing the risk of male infertility.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14–17 of this
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease
risk claims and claims referring to children’s development and health in a Community list of permitted
claims.
According to of this Regulation, an application for shall be submitted by the applicant to the national
competent authority of a Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion
on the scientiﬁc substantiation of a health claim related to: Condensyl® and decreases sperm DNA
damage.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of Condensyl®, a positive assessment of its safety, nor a decision on whether Condensyl®
is, or is not, classiﬁed as a foodstuff. It should be noted that such an assessment is not foreseen in the
framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 17 of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
2.1.1. Information provided by the applicant
Food/constituent as stated by the applicant
According to the applicant, the food constituent that is the subject of the claim is Condensyl®, a
ﬁxed combination of opuntia fruit dry extract standardised in quercetin and betalain, N-acetyl cysteine,
zinc, vitamin B3, E, B6, B2, B9 and B12.
Health relationship as claimed by the applicant
According to the applicant, the food Condensyl® reduces sperm DNA damage (sperm nuclear
decondensation index and DNA fragmentation index), high sperm DNA damage being a risk factor for
male subfertility/infertility.
Mechanism by which the food/constituent could exert the claimed effect as proposed by
the applicant
According to the applicant, the effect of Condensyl® could be explained by boosting S-Adenosyl
Methionine (SAM) production by folic acid as the methyl donor, and all the cofactors for the concerned
enzymes, namely vitamins B2, B3, B6 and B12, and zinc. The synthesis of glutathione (GSH) is
supported by the SAM (activating cystathionine b-synthase - CBS) induced as such and further boosted
by the supplementation of acetyl cysteine acting as the cysteine donor and zinc and vitamin B6 as the
necessary CBS cofactors. Small amount of vitamin E, quercetin and betalains from nopal provide some
protection to the cell membranes from excessive peroxidation.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
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Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘The combination of opuntia
fruit dry extract standardised in quercetin and betalain, N-acetyl cysteine, zinc, vitamin B3, E, B6, B2,
B9 and B12 in Condensyl® decreases sperm DNA damage (sperm nuclear decondensation index and
DNA fragmentation index). High sperm DNA damage (sperm nuclear decondensation index and DNA
fragmentation index) is a risk factor for male subfertility/infertility’.
Speciﬁc conditions of use as proposed by the applicant
The applicant has proposed an intake of two tablets of Condensyl® daily. The target population
proposed by the applicant is the healthy male population with high DNA fragmentation index (DFI) and
high nuclear decondensation index (SDI).
Data provided by the applicant
Health claim application on Condensyl® decreases the sperm DNA damage. High sperm DNA
damage is a risk factor for male dysfertility/infertility pursuant to Article 14 of Regulation 1924/2006,
presented in a common and structured format as outlined in the Scientiﬁc and technical guidance for
the preparation and presentation of applications for authorisation of health claims.2
As outlined in the General guidance for stakeholders on health claim applications,3 it is the
responsibility of the applicant to provide the totality of the available evidence.
This health claim application does not include a request for the protection of proprietary data in
accordance with Article 21 of Regulation (EC) No 1924/2006.
Data related to the manufacturing process of Condensyl® presented in the application are
conﬁdential to Laboratoire Nurilia.
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claims applications is outlined
in the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016).
3. Assessment
3.1. Characterisation of the food/constituent
The food/constituent which is proposed by the applicant to be the subject of the health claim is
Condensyl®, a tablet containing a ﬁxed combination of opuntia fruit dry extract (Nopal pulpe violin
powder) (100 mg), N-acetyl cysteine (250 mg), zinc (15 mg), nicotinamide (16 mg), vitamin E
(succinate) (12 mg), vitamin B6 (pyridoxine) (1.4 mg), vitamin B2 (riboﬂavin) (1.4 mg), folic acid
(0.40 mg) and vitamin B12 (cyanocobalamin) (2.5 lg). Nopal (Opuntia ﬁcus indica (L.) Mill.) powder is
standardised for the content of quercetin (5 mg/100 g), indicaxanthin (13.2 mg/100 g) and betanin
(28.8 mg/100 g). The total weight of the tablet is 880 mg.
An overview of the manufacturing process, batch-to-batch variability and stability data were provided.
The Panel considers that the food/constituent Condensyl®, which is the subject of the health claim,
is sufﬁciently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘reduction of sperm DNA damage (sperm nuclear
decondensation index and DNA fragmentation index), high sperm DNA damage being a risk factor for
male subfertility/infertility’. The proposed target population is ‘healthy males with high DNA
Fragmentation Index (DFI) and Nuclear Decondensation Index (SDI)’. Upon a request for clariﬁcation
from EFSA, the applicant stated that the target population for the claim is ‘males in reproductive age
with unknown reason leading to subfertility’.
2 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuh€auser-Berthold M, Nowicka G,
Pentieva K, Sanz Y, Sj€odin A, Stern M, Tome D, Van Loveren H, Vinceti M, Willatts P, Martin A, Strain JJ, Heng L, Valtuena
Martınez S and Siani A, 2017. Scientiﬁc and technical guidance for the preparation and presentation of a health claim
application (Revision 2). EFSA Journal 2017;15(1):4680, 31 pp. https://doi.org/10.2903/j.efsa.2017.4680
3 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016. General scientiﬁc guidance for stakeholders
on health claim applications. EFSA Journal 2016;14(1):4367, 38 pp. https://doi.org/10.2903/j.efsa.2016.4367
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The Panel notes that the term ‘subfertility’ has not been deﬁned by the applicant. The Panel also
notes that infertility is clinically deﬁned by the failure to achieve a clinical pregnancy after 12 months
or more of regular unprotected sexual intercourse (Zegers-Hochschild et al., 2009).
In this context, the Panel assumes that the disease that is the subject of the application is male
infertility and that the target population for the claim includes males wishing to increase their fertility
but excludes males with clinical infertility.
According to the applicant, ‘reduction of sperm DNA damage may contribute to the fertility of men.
Sperm DNA integrity may be affected by DNA fragmentation and formation of DNA adducts (primary
and secondary structure) and DNA decondensation (tertiary structure). Sperm integrity may be
measured by a number of methods, e.g. sperm chromatin structure assay (SCSA), the
deoxynucleotidyl transferase-mediated dUTP nick and labelling assay (TUNEL), the single-cell gel
electrophoresis assay (the comet assay) and the sperm chromatin dispersion test (SCD). Several
studies have shown that increased sperm DNA damage (measured e.g. by DFI and SDI) is associated
with decreased embryo quality, decreased pregnancy rates and higher rates of spontaneous
miscarriage’.
Upon a request from EFSA to provide evidence that a modiﬁcation of the risk factor (sperm DNA
damage) prospectively modiﬁes the risk of the disease (male infertility), the applicant did not identify
any studies supporting this effect. The Panel notes that the applicant did not provide evidence to
establish that a reduction of sperm DNA damage decreases the risk of male infertility.
As stated in the EFSA general guidance on health claims applications (EFSA NDA Panel, 2016), if
there is no evidence from intervention studies that a reduction of the risk factor generally reduces the
incidence of disease, but there is evidence for an independent association between the proposed risk
factor and the incidence of the disease from observational studies and the involvement of the risk
factor in the development of the disease is biologically plausible, a reduction of the risk factor may be
considered a beneﬁcial physiological effect in the context of a reduction of disease risk claim. In this
case, evidence that the dietary intervention with the speciﬁc food/constituent induces both a reduction
of the risk factor and a reduction of the risk of disease (preferably in the same study), needs to be
provided.
In the context of this application, therefore, the Panel considers that the reduction of DNA sperm
damage is a beneﬁcial physiological effect in the context of reducing the risk of male infertility, as long
as evidence is provided that Condensyl® induces a reduction in both DNA sperm damage and male
infertility.
3.3. Scientiﬁc substantiation of the claimed effect
The applicant performed a literature search in Medline, and Google scholar with the following key
words: “Condensyl”, “sperm DNA fragmentation”, “sperm nuclear decondensation”, “fertility”. No
restrictions were applied. A manual search was also performed.
The applicant provided four human intervention studies as being pertinent to the claim.
One study (Cornet et al., 2015) evaluated the effects of Procrelia ManTM, a product not complying
with the speciﬁcations given in Section 3.1 for the food for which the claim is proposed. Another was a
single-arm study conducted in males with established clinical infertility with no control group (Dattilo
et al., 2014). Both studies were conducted in males with established clinical infertility and two
unsuccessful assisted reproductive technology (ART) procedures. The third publication reported on one
case of successful pregnancy after 2 years of Condensyl® consumption by the male in a couple with a
history of infertility (Junca et al., 2012). The fourth study (Amar et al., 2015) was a parallel, three-arm,
non-randomised, open-label study which compared the effect of Condensyl® alone with the effects of
a sequential treatment with Fertibiol® and Condensyl® and with no treatment (control). All male
participants were under consultation for primary infertility (duration > 3 years) with previous in vitro
fertilisation (IVF) or intra-cytoplasmic sperm injection (ICSI) attempts.
The Panel notes all these studies were conducted in males with established clinical infertility and
that they relate to the treatment of the disease, and therefore, the effect of the intervention on the
incidence of male infertility cannot be assessed. In addition, the Panel notes that two of these studies
had no control group (Junca et al., 2012; Dattilo et al., 2014), and that a third study was conducted
with a product not complying with the speciﬁcations given in Section 3.1 for the food for which the
claim is proposed (Cornet et al., 2015). The Panel considers that no conclusions can be drawn from
these studies for the scientiﬁc substantiation of the claim.
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In the absence of evidence for an effect of Condensyl® in reducing sperm DNA damage and the
risk of male infertility in vivo in humans, the studies provided by the applicant on the proposed
mechanisms by which Condensyl® could exert the claimed effect were not considered by the Panel for
the scientiﬁc substantiation of the claim.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of Condensyl® and reduction of DNA sperm damage in the context of reducing the risk of
male infertility.
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• the food/constituent, Condensyl®, which is the subject of the health claim, is sufﬁciently
characterised.
• the claimed effect proposed by the applicant is ‘reduction of sperm DNA damage (sperm
nuclear decondensation index and DNA fragmentation index); high sperm DNA damage being
a risk factor for male subfertility/infertility’. The target population proposed by the applicant is
‘males in reproductive age with unknown reason leading to subfertility’. The Panel assumes
that the disease that is the subject of the application is male infertility and that the target
population for the claim includes males wishing to increase their fertility but excludes males
with clinical infertility. Reduction of sperm DNA damage is a beneﬁcial physiological effect in
the context of reducing the risk of male infertility.
• A cause and effect relationship has not been established between the consumption of
Condensyl® and reduction of sperm DNA damage in the context of reducing the risk of male
infertility.
Steps taken by EFSA
1) Health claim application on Condensyl® and decrease of sperm DNA damage pursuant to
Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 04450_FR). Submitted by
Laboratoire Nurilia, 78/80 rue Boileau, 69000 Lyon, France.
2) This application was received by EFSA on 18/10/2016.
3) The scope of the application was proposed to fall under a health claim referring to disease
risk reduction.
4) The scientiﬁc evaluation procedure started on 21/11/2016.
5) On 12/12/2016, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientiﬁc evaluation was suspended on 15/12/2016 and was restarted on 28/2/2017, in
compliance with Article 16(1) of Regulation (EC) No 1924/2006.
6) On 28/2/2017, EFSA received the applicant’s reply (which was made available to EFSA in
electronic format on 28/2/2017).
7) During its meeting on 4/4/2017, the NDA Panel, having evaluated the data, adopted an
opinion on the scientiﬁc substantiation of a health claim related to Condensyl® and decrease
of sperm DNA damage in the context of reducing the risk of male infertility.
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ART assisted reproductive technology
CBS cystathionine b-synthase
DFI DNA Fragmentation Index
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SCSA sperm chromatin structure assay
SDI nuclear decondensation index
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